Your browser doesn't support javascript.
loading
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.
Marks, Michael; Millat-Martinez, Pere; Ouchi, Dan; Roberts, Chrissy H; Alemany, Andrea; Corbacho-Monné, Marc; Ubals, Maria; Tobias, Aurelio; Tebé, Cristian; Ballana, Ester; Bassat, Quique; Baro, Bàrbara; Vall-Mayans, Martí; G-Beiras, Camila; Prat, Nuria; Ara, Jordi; Clotet, Bonaventura; Mitjà, Oriol.
Afiliação
  • Marks M; Clinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, University College London Hospital, London, UK. Electronic address: michael.marks@lshtm.ac.uk.
  • Millat-Martinez P; Barcelona Institute for Global Health, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Ouchi D; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Roberts CH; Clinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
  • Alemany A; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Corbacho-Monné M; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain.
  • Ubals M; Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Tobias A; Institute of Environmental Assessment and Water Research, Spanish Council for Scientific Research, Barcelona, Spain.
  • Tebé C; Biostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Ballana E; IrsiCaixa AIDS Research Institute, Badalona, Spain; Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Bassat Q; Barcelona Institute for Global Health, Hospital Clínic, University of Barcelona, Barcelona, Spain; Catalan Institution for Research and Advanced Studies, Barcelona, Spain.
  • Baro B; Barcelona Institute for Global Health, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Vall-Mayans M; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • G-Beiras C; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Prat N; Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Ara J; Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Clotet B; IrsiCaixa AIDS Research Institute, Badalona, Spain; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Càtedra de Malalties Infeccioses i Immunitat, Universitat de Vic, Universtiat Central de Ca
  • Mitjà O; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Càtedra de Malalties Infec
Lancet Infect Dis ; 21(5): 629-636, 2021 05.
Article em En | MEDLINE | ID: mdl-33545090
BACKGROUND: Scarce data are available on what variables affect the risk of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the development of symptomatic COVID-19, and, particularly, the relationship with viral load. We aimed to analyse data from linked index cases of COVID-19 and their contacts to explore factors associated with transmission of SARS-CoV-2. METHODS: In this cohort study, patients were recruited as part of a randomised controlled trial done between March 17 and April 28, 2020, that aimed to assess if hydroxychloroquine reduced transmission of SARS-CoV-2. Patients with COVID-19 and their contacts were identified by use of the electronic registry of the Epidemiological Surveillance Emergency Service of Catalonia (Spain). Patients with COVID-19 included in our analysis were aged 18 years or older, not hospitalised, had quantitative PCR results available at baseline, had mild symptom onset within 5 days before enrolment, and had no reported symptoms of SARS-CoV-2 infections in their accommodation or workplace within the 14 days before enrolment. Contacts included were adults with a recent history of exposure and absence of COVID-19-like symptoms within the 7 days preceding enrolment. Viral load of contacts, measured by quantitative PCR from a nasopharyngeal swab, was assessed at enrolment, at day 14, and whenever the participant reported COVID-19-like symptoms. We assessed risk of transmission and developing symptomatic disease and incubation dynamics using regression analysis. We assessed the relationship of viral load and characteristics of cases (age, sex, number of days from reported symptom onset, and presence or absence of fever, cough, dyspnoea, rhinitis, and anosmia) and associations between risk of transmission and characteristics of the index case and contacts. FINDINGS: We identified 314 patients with COVID-19, with 282 (90%) having at least one contact (753 contacts in total), resulting in 282 clusters. 90 (32%) of 282 clusters had at least one transmission event. The secondary attack rate was 17% (125 of 753 contacts), with a variation from 12% when the index case had a viral load lower than 1 × 106 copies per mL to 24% when the index case had a viral load of 1 × 1010 copies per mL or higher (adjusted odds ratio per log10 increase in viral load 1·3, 95% CI 1·1-1·5). Increased risk of transmission was also associated with household contact (3·0, 1·59-5·65) and age of the contact (per year: 1·02, 1·01-1·04). 449 contacts had a positive PCR result at baseline. 28 (6%) of 449 contacts had symptoms at the first visit. Of 421 contacts who were asymptomatic at the first visit, 181 (43%) developed symptomatic COVID-19, with a variation from approximately 38% in contacts with an initial viral load lower than 1 × 107 copies per mL to greater than 66% for those with an initial viral load of 1 × 1010 copies per mL or higher (hazard ratio per log10 increase in viral load 1·12, 95% CI 1·05-1·20; p=0·0006). Time to onset of symptomatic disease decreased from a median of 7 days (IQR 5-10) for individuals with an initial viral load lower than 1 × 107 copies per mL to 6 days (4-8) for those with an initial viral load between 1 × 107 and 1 × 109 copies per mL, and 5 days (3-8) for those with an initial viral load higher than 1 × 109 copies per mL. INTERPRETATION: In our study, the viral load of index cases was a leading driver of SARS-CoV-2 transmission. The risk of symptomatic COVID-19 was strongly associated with the viral load of contacts at baseline and shortened the incubation time of COVID-19 in a dose-dependent manner. FUNDING: YoMeCorono, Generalitat de Catalunya. TRANSLATIONS: For the Catalan translation of the abstract see Supplementary Materials section.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article